Springworks Therapeutics, Inc. (SWTX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 07, 2025

$41.20

P/E Ratio

N/A

Market Cap

$3.06B

Jan 22, 2024Feb 26, 2024Apr 1, 2024May 2, 2024Jun 5, 2024Jul 9, 2024Aug 8, 2024Sep 12, 2024Oct 17, 2024Nov 21, 2024Jan 7, 2025$20.00$30.00$40.00$50.00$60.00
  • SWTX
Description

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

Metrics

Overview

  • HQStamford, CT
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerSWTX
  • Price$41.2+6.02%

Trading Information

  • Market cap$3.06B
  • Float88.57%
  • Average Daily Volume (1m)1,132,078
  • Average Daily Volume (3m)1,152,937
  • EPS-$3.73

Company

  • Revenue$135.49M
  • Rev growth (1yr)N/A
  • Net income-$53.53M
  • Gross margin91.44%
  • EBITDA margin-115.74%
  • EBITDA-$57.06M
  • EV$2.01B
  • EV/Revenue14.83
  • P/EN/A
  • P/S22.58
  • P/B5.75
Documents